Literature DB >> 23329398

A new strategy for treatment of liver fibrosis: letting MicroRNAs do the job.

Shao-Long Chen1, Ming-Hua Zheng, Ke-Qing Shi, Tao Yang, Yong-Ping Chen.   

Abstract

MicroRNAs (miRNAs) are short, endogenous, noncoding RNA molecules that regulate gene expression at a post-translational level. MiRNAs have been recognized in the regulation of physiological conditions. Moreover, awareness of the association between dysregulated miRNAs and human diseases is increasing, which consequently brings miRNAs to the frontline in the development of novel therapeutic strategies. We review the latest advances in our knowledge of the involvement of miRNAs in fibrosis with particular emphasis on hepatic fibrosis and the possibilities in the near future for miRNA-based therapy for targeted treatment of liver fibrosis. With recent advances in our understanding of the important role of senescence in the resolution of activated hepatic stellate cells (HSCs), we suggested the therapeutic potential of inducing activated HSCs into senescence by an miRNA-based strategy.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23329398     DOI: 10.1007/s40259-012-0005-2

Source DB:  PubMed          Journal:  BioDrugs        ISSN: 1173-8804            Impact factor:   5.807


  17 in total

1.  The mechanisms of HSC activation and epigenetic regulation of HSCs phenotypes.

Authors:  Agata Page; Derek A Mann; Jelena Mann
Journal:  Curr Pathobiol Rep       Date:  2014-09-27

2.  MicroRNA Expression in Focal Nodular Hyperplasia in Comparison with Cirrhosis and Hepatocellular Carcinoma.

Authors:  Gábor Lendvai; Tímea Szekerczés; Benedek Gyöngyösi; Krisztina Schlachter; Endre Kontsek; Adrián Pesti; Attila Patonai; Klára Werling; Ilona Kovalszky; Zsuzsa Schaff; András Kiss
Journal:  Pathol Oncol Res       Date:  2018-11-09       Impact factor: 3.201

Review 3.  Delivery and targeting of miRNAs for treating liver fibrosis.

Authors:  Virender Kumar; Ram I Mahato
Journal:  Pharm Res       Date:  2014-09-04       Impact factor: 4.200

4.  miR-122 negatively correlates with liver fibrosis as detected by histology and FibroScan.

Authors:  Tünde Halász; Gábor Horváth; Gabriella Pár; Klára Werling; András Kiss; Zsuzsa Schaff; Gábor Lendvai
Journal:  World J Gastroenterol       Date:  2015-07-07       Impact factor: 5.742

Review 5.  Pathogenesis of liver cirrhosis.

Authors:  Wen-Ce Zhou; Quan-Bao Zhang; Liang Qiao
Journal:  World J Gastroenterol       Date:  2014-06-21       Impact factor: 5.742

6.  Histological outcome for chronic hepatitis B patients treated with entecavir vs lamivudine-based therapy.

Authors:  Jia-Li Wang; Xin-Fang Du; Shao-Long Chen; Yi-Qi Yu; Jing Wang; Xi-Qi Hu; Ling-Yun Shao; Jia-Zhen Chen; Xin-Hua Weng; Wen-Hong Zhang
Journal:  World J Gastroenterol       Date:  2015-08-28       Impact factor: 5.742

7.  Givinostat inhibition of hepatic stellate cell proliferation and protein acetylation.

Authors:  Yu-Gang Wang; Ling Xu; Ting Wang; Jue Wei; Wen-Ying Meng; Na Wang; Min Shi
Journal:  World J Gastroenterol       Date:  2015-07-21       Impact factor: 5.742

8.  MicroRNA-221 is required for proliferation of mouse embryonic stem cells via P57 targeting.

Authors:  Jin Li; Yihua Bei; Qi Liu; Dongchao Lv; Tianzhao Xu; Yanyun He; Ping Chen; Junjie Xiao
Journal:  Stem Cell Rev Rep       Date:  2015-02       Impact factor: 5.739

Review 9.  Epigenetics in liver disease.

Authors:  Derek A Mann
Journal:  Hepatology       Date:  2014-05-07       Impact factor: 17.425

10.  Low Levels of MicroRNA-21 Are a Marker of Reduced Arterial Stiffness in Well-Controlled Hypertension.

Authors:  Fragiskos Parthenakis; Maria Marketou; Joanna Kontaraki; Alexandros Patrianakos; Helen Nakou; Maria Touloupaki; Michail Vernardos; George Kochiadakis; Gregory Chlouverakis; Panos Vardas
Journal:  J Clin Hypertens (Greenwich)       Date:  2016-08-22       Impact factor: 3.738

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.